吉利德科学Gilead Sciences (GILD) 2007年年度报告「NASDAQ」.pdf

1、2007 Annual ReportHaving perspective.Gilead Sciences is a research-based biopharmaceutical company working to expand treatment options and improve the care of people with life-threatening diseases.We have a broad perspective on the challenges we face,and at the same time we maintain a clear focus on

2、 the individuals we serve.The nearly 3,000 employees at Gilead are dedicated to innovation and excellence in all that we do.23 Not concerned about AIDS Isnt always safe Five years since last HIV testApproximately 1.2 million Americans are living with HIV,the virus that causes AIDS.Half arent being t

3、reated.One-quarter dont even know theyre infected.4 About half a million people worldwide are currently taking one of Gileads four antiretroviral therapies.By discovering and developing new medicines,simplifying treatment regimens and supporting efforts to expand HIV testing,diagnosis and treat-ment

4、 access,we aim to improve the lives of even more people around the world.67 Not immunized against HBV Father has liver cancer Unaware hes at risk Only a small fraction of the estimated 400 million people worldwide who are chronically infected with the hepatitis B virus(HBV)are receiving treatment.On

5、e in four will die from complications associated with the disease.8 Gileads Hepsera is a leading antiviral treatment for chronic hepatitis B.We expect to have another hepatitis B therapy on the market in the second half of 2008.That drug,Viread,is already available as part of combination therapy for

6、 the treatment of HIV infection.We are also developing drugs for the treatment of hepatitis C infection.1011 Has never heard of PAH Tires easily when walking her dog Recently fainted Pulmonary arterial hypertension(PAH)is a rare but often fatal disease.If left untreated,PAH patients usually die with